Cabotegravir/rilpivirine (Cabenuva) vs Doravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Cabotegravir/rilpivirine (Cabenuva)
Marketed by GlaxoSmithKline
NCT05917509 · Phase 3 · completed
The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT06411223 (registry estimate)
Reported efficacy
Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)
Result source: NCT03299049
Doravirine · Pifeltro
Marketed by Merck & Co.
NCT02275780 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)
Result source: NCT02403674
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cabotegravir/rilpivirine (Cabenuva) | Doravirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352125 other results
| 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757803 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 0%vs DTG + RPVNCT03639311 | 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778 |
| CD4 count, change (week 48) | 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT0212035236 other results
| 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578014 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352
125 other results
- 95% vs 91% NCT02120352
- 80% vs 71% NCT01641809
- 87% vs 71% NCT01641809
- 80% vs 71% NCT01641809
- 75% vs 63% NCT01641809
- 85% vs 83% NCT01641809
- 75% vs 68% NCT01641809
- 72% vs 0% NCT01641809
- 85% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 73% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 70% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 67% vs 0% NCT01641809
- 91% vs 94% NCT01641809
- 82% vs 68% NCT01641809
- 92% vs 89% NCT01641809
- 82% vs 71% NCT01641809
- 63% vs 0% NCT01641809
- 92% vs 94% NCT01641809
- 80% vs 69% NCT01641809
- 91% vs 91% NCT01641809
- 78% vs 69% NCT01641809
- 89% vs 91% NCT01641809
- 75% vs 66% NCT01641809
- 85% vs 87% NCT01641809
- 85% vs 74% NCT01641809
- 65% vs 0% NCT01641809
- 94% vs 96% NCT01641809
- 67% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 60% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 84% vs 63% NCT01641809
- 93% vs 83% NCT01641809
- 85% vs 68% NCT01641809
- 80% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 80% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 80% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 87% vs 71% NCT01641809
- 77% vs 0% NCT01641809
- 96% vs 94% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 80% vs 0% NCT01641809
- 95% vs 94% NCT01641809
- 87% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 95% vs 91% NCT01641809
- 85% vs 66% NCT01641809
- 95% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 75% vs 0% NCT01641809
- 96% vs 96% NCT01641809
- 75% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 68% vs 63% NCT01641809
- 79% vs 83% NCT01641809
- 72% vs 68% NCT01641809
- 68% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 72% vs 68% NCT01641809
- 65% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 78% vs 68% NCT01641809
- 62% vs 0% NCT01641809
- 90% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 58% vs 0% NCT01641809
- 92% vs 94% NCT01641809
- 83% vs 68% NCT01641809
- 96% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 58% vs 0% NCT01641809
- 98% vs 94% NCT01641809
- 83% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 98% vs 91% NCT01641809
- 78% vs 66% NCT01641809
- 90% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 57% vs 0% NCT01641809
- 96% vs 96% NCT01641809
- 58% vs 0% NCT01641809
- 57% vs 0% NCT01641809
- 55% vs 0% NCT01641809
- 55% vs 0% NCT01641809
- 53% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 53% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 98% vs 100% NCT03639311
- Doravirine
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
3 other results
- 84.3% vs 80.8% NCT02403674
- 73.1% vs 66% NCT02275780
- 77.5% vs 73.6% NCT02403674
HIV-1 RNA 50 copies/mL or more (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 0% vs 0%vs DTG + RPVNCT03639311
- Doravirine
- 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778
CD4 count, change (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT02120352
36 other results
- 263.7 vs 346.1 NCT02120352
- 257.5 vs 369.9 NCT02120352
- 264.4 vs 346.1 NCT02120352
- 267.5 vs 281.7 NCT01641809
- 287 vs 279.4 NCT01641809
- 201.4 vs 257.1 NCT01641809
- 269.4 vs 263.8 NCT01641809
- 241.6 vs 262.5 NCT01641809
- 212.8 vs 221.5 NCT01641809
- 213 vs 185.2 NCT01641809
- 205.2 vs 197.4 NCT01641809
- 188.1 vs 178.2 NCT01641809
- 177.7 vs 166.4 NCT01641809
- 180.9 vs 143.4 NCT01641809
- 286.2 vs 281.7 NCT01641809
- 278.1 vs 279.4 NCT01641809
- 254 vs 257.1 NCT01641809
- 266.1 vs 263.8 NCT01641809
- 259 vs 262.5 NCT01641809
- 212.3 vs 221.5 NCT01641809
- 265 vs 185.2 NCT01641809
- 209.9 vs 197.4 NCT01641809
- 193.3 vs 178.2 NCT01641809
- 194.7 vs 166.4 NCT01641809
- 204 vs 143.4 NCT01641809
- 269.4 vs 281.7 NCT01641809
- 261.5 vs 279.4 NCT01641809
- 232 vs 257.1 NCT01641809
- 217.7 vs 263.8 NCT01641809
- 235.1 vs 262.5 NCT01641809
- 203.6 vs 221.5 NCT01641809
- 192 vs 185.2 NCT01641809
- 191.4 vs 197.4 NCT01641809
- 205 vs 178.2 NCT01641809
- 186.4 vs 166.4 NCT01641809
- 172.5 vs 143.4 NCT01641809
- Doravirine
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
14 other results
- 192.7 vs 185.6 NCT02275780
- 217.1 vs 319.9 NCT04233879
- 182.4 vs 233.5 NCT04233879
- 5.4 vs 62.7 NCT04223791
- -19.7 vs 40.5 NCT04223791
- 0.5 vs 66.3 NCT04223791
- 239.6 vs 350.9 NCT04233879
- 259.2 vs 263.6 NCT01632345
- 191.9 vs 194.5 NCT01632345
- 133.6 vs 121.1 NCT01632345
- 152.3 vs 146 NCT01632345
- 140.7 vs 121.1 NCT01632345
- 112.9 vs 121.1 NCT01632345
- 154.1 vs 121.1 NCT01632345
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Cabotegravir/rilpivirine (Cabenuva): 10 of 10 rows · Doravirine: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cabotegravir/rilpivirine (Cabenuva) Rows use multiple source trials | Doravirine Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 276 cells/uL @ 324wk30 mga,b,c,d,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses272 cells/uL @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 402 cells/uL @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 42.5 cells/uL @ 96wkb,c,d,e NCT03332095 · Phase 1/2 · combination |
| HIV-1 RNA absolute change · log Induction | -1.577 vs -0.168 placebo log @ 1wk5 mgf,c,g NCT00920426 · Phase 2 · registry result, not featured evidence | -1.23 vs 0.03 placebo log @ 1wka,f,c,g NCT04233216 · Phase 3 · registry result, not featured evidence · combination show 1 more dose-1.23 vs -0.44 ISL log @ 1wk NCT04233216 · Phase 3 · registry result, not featured evidence · combination |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.215 log @ 324wk30 mga,b,c,d,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.438 log @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.488 log @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -4.3 log @ 96wkb,c,d,e NCT03332095 · Phase 1/2 · combination |
| HIV-1 RNA Ge50 Copies responder rate · % of participants No placebo or comparator arm | 2.2% (n=93) @ 12wk400 mg + 600 mg Q4Wh,c,g,i NCT05896748 · Phase 3 · registry result, not featured evidence · combination | 2.9% (n=34) @ 24wkh,c,g,i NCT04295772 · Phase 2 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 87% (n=430) @ 52wkj,c,g,k NCT04399551 · Phase 3 · registry result, not featured evidence | 92.5% (n=40) @ 96wkj,c,g,k NCT03332095 · Phase 1/2 · combination |
| Virologic Failure event count · % of participants Maintenance | 0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4Wa,l,m NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted show 1 more dose1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted | 0% (n=47) vs 0% (n=49) INSTI+TAF/FTC @ 48wk*100 mga,l,m NCT04636437 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted show 1 more dose0% (n=49) vs 0% (n=49) INSTI+TAF/FTC @ 48wk*100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted |
| Dropout rate | 13.6%n NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 8.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 13.1%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 6.5% NCT04399551 · Phase 3 · registry result, not featured evidence 11.3% NCT04001803 · Phase 3 · registry result, not featured evidence 1.3%CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 15.6%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 11.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 13.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 15.2%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 24.2%100 mgo NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 19.6%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 10%Cohort 1: DOR NCT03332095 · Phase 1/2 2.2%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 20.4%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 8.2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 0% NCT04689737 · Phase 4 · registry result, not featured evidence 30.4%DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 80.2%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 17%Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 42.9%DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 33.3%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 43.6%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 28.6% NCT04900974 · Phase 1 · registry result, not featured evidence 0% NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —n NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 5.7%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 3.5% NCT04399551 · Phase 3 · registry result, not featured evidence 4.3% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 1.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 1.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 4.9%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence —30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 1.6%100 mgo NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 3%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 —Cohort 1: DOR NCT03332095 · Phase 1/2 —Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination — NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence — NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination —200 mg NCT01466985 · Phase 1 · registry result, not featured evidence —25 mg NCT01466985 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%n NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 3.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 6.3%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence 3.4%Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 4% NCT04399551 · Phase 3 · registry result, not featured evidence 7.8% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 12.7%Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 10%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 26.5%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 11.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 0%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.4%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 17%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.1%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.6%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 15.2%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 12.5%Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03149848 · Phase 1 · registry result, not featured evidence 7.1%300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 11.7%100 mgo NCT02275780 · Phase 3 · combination show 44 more results6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 6%DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 4.5%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 5.2%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 6.3%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 8.2%DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 —MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 0%Cohort 1: DOR NCT03332095 · Phase 1/2 4.4%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 10.6%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 25% NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 4.3%DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 6.2%DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.6%DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.5%DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 6.4%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 5.3%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.1%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 0%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.7%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.8%Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence 4%Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence 3.7%Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 2.7%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 10.2%100 mg NCT01632345 · Phase 2 · registry result, not featured evidence 7.3%200 mg NCT01632345 · Phase 2 · registry result, not featured evidence 2.3%50 mg NCT01632345 · Phase 2 · registry result, not featured evidence 10%25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 0% NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | n injection site discomfort 13.6% injection site pain 13.6% fatigue 2.3% NCT04982445 · Phase 4 · registry result, not featured evidence show 40 more results400 mg + 600 mg Q4W injection site pain 32.3% injection site nodule 9.7% injection site induration 2.2% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 74.2% injection site nodule 64.5% injection site erythema 51.6% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 30.9% injection site nodule 3.2% injection site pruritus 2.1% NCT05896748 · Phase 3 · registry result, not featured evidence · combination injection site pain 65.2% covid-19 17.9% headache 12.5% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 60.6% covid-19 19.4% injection site induration 11.4% NCT04542070 · Phase 3 · registry result, not featured evidence Q2M injection site pain 37.9% covid-19 14.5% arthralgia 0% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 80.2% covid-19 18.4% injection site induration 11.2% NCT04399551 · Phase 3 · registry result, not featured evidence injection site pain 55.7% injection site discomfort 26.1% fatigue 20% NCT04001803 · Phase 3 · registry result, not featured evidence creatinine renal clearance decreased 19.7% lipase increased 11.3% chills 7% NCT03739996 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 99.1% injection site nodule 49.6% nasopharyngitis 47% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 80% injection site nodule 50% nasopharyngitis 50% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 96.5% nasopharyngitis 47% injection site nodule 40% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 91.2% injection site nodule 35.3% covid-19 26.5% NCT02120352 · Phase 2 · registry result, not featured evidence · combination Q2M injection site pain 74.4% covid-19 33.3% upper respiratory tract infection 17.8% NCT03639311 · Phase 2 · registry result, not featured evidence · combination 30 mg headache 21.7% nausea 18.3% upper respiratory tract infection 13.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 26.4% diarrhoea 13.2% rash 11.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 31.9% back pain 12.8% oropharyngeal pain 12.8% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg headache 21.3% diarrhoea 18% nausea 18% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 21.8% nausea 14.5% bronchitis 10.9% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 27.5% anxiety 11.8% sinusitis 11.8% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg nausea 23.3% headache 21.7% diarrhoea 16.7% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg upper respiratory tract infection 17.3% depression 9.6% diarrhoea 9.6% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg diarrhoea 13% nasopharyngitis 10.9% gonorrhoea 8.7% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg dizziness 37.5% (placebo 0%) dyspepsia 25% (placebo 0%) headache 25% (placebo 0%) NCT00920426 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain 0% (placebo 0%) abnormal dreams 0% (placebo 0%) blood bilirubin increased 0% (placebo 50%) NCT00920426 · Phase 2 · registry result, not featured evidence 30 mg atrioventricular block first degree 7.7% decreased appetite 7.7% headache 7.7% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% aspartate aminotransferase increased 50% blood creatine phosphokinase increased 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site nodule 55.6% injection site erythema 44.4% NCT04484337 · Phase 1 · registry result, not featured evidence injection site haemorrhage 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 72.7% injection site pain 72.7% injection site induration 45.5% NCT04484337 · Phase 1 · registry result, not featured evidence injection site induration 100% injection site pain 100% injection site bruising 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 75% headache 37.5% injection site swelling 37.5% NCT04484337 · Phase 1 · registry result, not featured evidence catheter site bruise 50% injection site erythema 50% injection site induration 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 94.4% headache 77.8% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 100% injection site pruritus 87.5% NCT04484337 · Phase 1 · registry result, not featured evidence · combination injection site erythema 100% injection site pain 100% injection site warmth 88.9% NCT04484337 · Phase 1 · registry result, not featured evidence · combination accident 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site swelling 70% headache 60% NCT04484337 · Phase 1 · registry result, not featured evidence 30 mg blood creatine phosphokinase increased 6.7% contusion 6.7% body temperature increased 0% NCT03149848 · Phase 1 · registry result, not featured evidence 300 mg + 30 mg body temperature increased 7.1% headache 7.1% hyperkeratosis 7.1% NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 100 mgo diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · combination show 33 more resultsnasopharyngitis 13.7% upper respiratory tract infection 7.2% headache 6.2% NCT02403674 · Phase 3 · HIV · phase 3 nasopharyngitis 9.7% upper respiratory tract infection 7.1% diarrhoea 6.3% NCT02403674 · Phase 3 · HIV · phase 3 aspartate aminotransferase increased 22.2% blood alkaline phosphatase increased 11.1% blood glucose increased 11.1% NCT03332095 · Phase 1/2 glomerular filtration rate decreased 55.6% alanine aminotransferase increased 46.7% blood creatinine increased 46.7% NCT03332095 · Phase 1/2 · combination 100 mg creatinine renal clearance decreased 10.6% low density lipoprotein increased 6.4% abdominal pain upper 2.1% NCT04636437 · Phase 4 · registry result, not featured evidence · combination 100 mg creatinine renal clearance decreased 8.2% aspartate aminotransferase increased 4.1% alanine aminotransferase increased 2% NCT04636437 · Phase 4 · registry result, not featured evidence · combination headache 8.1% covid-19 5.9% arthralgia 5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 13.1% lymphocyte count decreased 10.5% cd4 lymphocytes decreased 9.2% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 32.3% cd4 lymphocytes decreased 23.7% covid-19 12.4% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 15.9% cd4 lymphocytes decreased 11.4% covid-19 1.5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 2.6% nasopharyngitis 2% diarrhoea 1% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 100 mg/0.75 mg covid-19 14.1% headache 10.4% lymphocyte count decreased 9.1% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 24.1% cd4 lymphocytes decreased 10.5% covid-19 7.5% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 17.1% cd4 lymphocytes decreased 8.2% upper respiratory tract infection 2.7% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 14.3% accidental overdose 0% arthralgia 0% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg upper respiratory tract infection 6.3% insomnia 1.8% headache 0.9% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 headache 10.7% accidental overdose 7.1% covid-19 5.4% NCT04223778 · Phase 3 · registry result, not featured evidence lymphocyte count decreased 20.2% cd4 lymphocytes decreased 14% covid-19 13% NCT04223778 · Phase 3 · registry result, not featured evidence covid-19 17.5% lymphocyte count decreased 13.5% cd4 lymphocytes decreased 12% NCT04223778 · Phase 3 · registry result, not featured evidence blood creatine phosphokinase increased 28.6% (placebo 14.3%) diarrhoea 28.6% (placebo 14.3%) anaemia 14.3% (placebo 0%) NCT04233216 · Phase 3 · registry result, not featured evidence · combination dizziness 33.3% dyspepsia 33.3% headache 33.3% NCT04295772 · Phase 2 · registry result, not featured evidence covid-19 100% adjustment disorder 0% back pain 0% NCT04295772 · Phase 2 · registry result, not featured evidence oropharyngeal pain 10.8% cough 8.1% nasal congestion 8.1% NCT04295772 · Phase 2 · registry result, not featured evidence cough 28.6% oropharyngeal pain 21.4% rhinorrhoea 21.4% NCT04295772 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 17.6% diarrhea 14.8% dizziness 14.8% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 29.3% nausea 22% headache 17.1% NCT01632345 · Phase 2 · registry result, not featured evidence 50 mg abnormal dreams 20.9% nausea 16.3% headache 14% NCT01632345 · Phase 2 · registry result, not featured evidence 25 mg diarrhea 25% fatigue 17.5% influenza 15% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 33.3%) abdominal pain 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence 25 mg alanine aminotransferase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 0%) decreased appetite 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 1/2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context differs: pooled versus combination.
- eAssessment timepoints differ: 324 weeks versus 96 weeks.
- fTrial phases differ: Phase 2 versus Phase 3.
- gTreatment context has not been resolved for both arms.
- hTrial phases differ: Phase 3 versus Phase 2.
- iAssessment timepoints differ: 12 weeks versus 24 weeks.
- jTrial phases differ: Phase 3 versus Phase 1/2.
- kAssessment timepoints differ: 52 weeks versus 96 weeks.
- lTrial phases differ: Phase 2 versus Phase 4.
- mPopulation context differs: registered conditions differ.
- nPopulation comparability has not been reviewed for these studies.
- oPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cabotegravir/rilpivirine (Cabenuva)
show 2 more results
show 1 more result
show 6 more results
show 25 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 163 further endpoints in the CSV export.
Doravirine
show 3 more results
show 3 more results
+ 35 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Doravirine's landscape